Literature DB >> 30191948

MicroRNA-384-3p inhibits retinal neovascularization through targeting hexokinase 2 in mice with diabetic retinopathy.

Fei Xia1, Juan-Juan Sun1, Ya-Qin Jiang2, Cheng-Fang Li3.   

Abstract

Diabetic retinopathy (DR) presents a microvascular complication of diabetes, which may contribute to visual impairment. The treatment of DR is still controversial. Accumulating studies have reported the role of microRNAs (miRs) in DR. This study aims to explore the functions of microRNA-384-3p (miR-384-3p) in retinal neovascularization by targeting hexokinase 2 (HK2) in mice with DR. A total of 43 C57BL/6 male mice were selected and divided into normal ( n = 16) and DR ( n = 27) groups. Retinal microvascular endothelial cells (RMECs) were collected from the normal and DR mice and mainly treated with a miR-384-3p mimic, a miR-384-3p inhibitor, small interfering RNA (siRNA) against HK2 and HK2 overexpression plasmids to understand the underlying regulatory mechanisms of miR-384-3p. The relationship between miR-384-3p and HK2 was determined by dual-luciferase reporter assay. The miR-384-3p expression and the mRNA and the protein expressions of HK2 and CD31 in retinal tissues and cells were evaluated using reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blot assay. Cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Tube formation was observed by conducting a tube formation experiment. HK2 is a target gene of miR-384-3p. The DR mice showed higher expression of HK2 and CD31 but lower expression of miR-384-3p. The miR-384-3p mimic and siRNA-HK2 reduced the expression of HK2, decreased cell proliferation and tube formation of RMECs, whereas the miR-384-3p inhibitor could reverse these trends. Our study demonstrates that overexpression of miR-384-3p inhibits retinal neovascularization in DR mice via inhibition of HK2.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD31; diabetic retinopathy (DR); hexokinase (HK2); microRNA-384-3p (miR-384-3p); retinal neovascularization

Mesh:

Substances:

Year:  2018        PMID: 30191948     DOI: 10.1002/jcp.26871

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  miR-139-5p promotes neovascularization in diabetic retinopathy by regulating the phosphatase and tensin homolog.

Authors:  Zhongwei Zhang; Caiping Song; Tao Wang; Lei Sun; Ling Qin; Jianghua Ju
Journal:  Arch Pharm Res       Date:  2021-02-20       Impact factor: 4.946

Review 2.  CircRNA-miRNA interactions in atherogenesis.

Authors:  Kind-Leng Tong; Ke-En Tan; Yat-Yuen Lim; Xin-Yi Tien; Pooi-Fong Wong
Journal:  Mol Cell Biochem       Date:  2022-05-23       Impact factor: 3.396

3.  MicroRNA-34a promotes apoptosis of retinal vascular endothelial cells by targeting SIRT1 in rats with diabetic retinopathy.

Authors:  Qingshan Ji; Jing Han; Lisong Wang; Jiajia Liu; Yiran Dong; Kai Zhu; Lei Shi
Journal:  Cell Cycle       Date:  2020-10-16       Impact factor: 4.534

4.  miR-125a-5p inhibits glycolysis by targeting hexokinase-II to improve pulmonary arterial hypertension.

Authors:  Li Luo; Lusheng Xiao; Guili Lian; Huajun Wang; Liangdi Xie
Journal:  Aging (Albany NY)       Date:  2020-05-19       Impact factor: 5.682

5.  Leptin Modulates the Expression of miRNAs-Targeting POMC mRNA by the JAK2-STAT3 and PI3K-Akt Pathways.

Authors:  Adel Derghal; Julien Astier; Flavie Sicard; Charlène Couturier; Jean-François Landrier; Lourdes Mounien
Journal:  J Clin Med       Date:  2019-12-14       Impact factor: 4.241

Review 6.  miRNA, lncRNA and circRNA: Targeted Molecules Full of Therapeutic Prospects in the Development of Diabetic Retinopathy.

Authors:  Xingyu Chang; Guomao Zhu; Zongyan Cai; Yaqi Wang; Rongna Lian; Xulei Tang; Chengxu Ma; Songbo Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-10       Impact factor: 5.555

7.  MicroRNA-18a-5p Administration Suppresses Retinal Neovascularization by Targeting FGF1 and HIF1A.

Authors:  Ji-Tian Guan; Xin-Xin Li; De-Wei Peng; Wen-Meng Zhang; Jia Qu; Fan Lu; Robert J D'Amato; Zai-Long Chi
Journal:  Front Pharmacol       Date:  2020-03-10       Impact factor: 5.810

8.  Editorial: Novel Therapeutic Target and Drug Development in Neurovascular Retinal Diseases.

Authors:  Zhuo Shao; Zhongxiao Wang; Amy C Y Lo; Zhongjie Fu
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 9.  The glycolytic process in endothelial cells and its implications.

Authors:  Susan Wai Sum Leung; Yi Shi
Journal:  Acta Pharmacol Sin       Date:  2021-04-13       Impact factor: 6.150

10.  MicroRNA-139-5p Alleviates High Glucose-Triggered Human Retinal Pigment Epithelial Cell Injury by Targeting LIM-Only Factor 4.

Authors:  Kan Shao; Gong Chen; Lili Xia; Cheng Chen; Shan Huang
Journal:  Mediators Inflamm       Date:  2021-10-23       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.